# Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

> **NCT01813019** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Patient Diagnosed With OCD and Resistant to SSRI Treatment
- Failed SSRI Over 12 Weeks at Appropriate Doses

## Interventions

- **DRUG:** AFQ056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01813019
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective.
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813019, "Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01813019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*